Winkler Robert E - Vifor Pharma | 人才画像

基本信息

浏览量：45

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 74 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Malignant Peripheral Nerve Sheath Tumor, a Heterogeneous, Aggressive Cancer with Diverse Biomarkers and No Targeted Standard of Care: Review of the Literature and Ongoing Investigational Agents

Neeta Somaiah,Bishnuhari Paudyal,Robert E. Winkler,Brian A. Van Tine,Angela C. Hirbe

Targeted oncologyno. 5 (2024): 665-678

引用0浏览0WOS引用

Phase I/II Study of A Novel MDM-2 Inhibitor (Apg-115-alrizomadlin) in P53 Wild Type Salivary Gland Cancers

A. Pearson,J. Muzaffar, K. Kirtane,E. Bellile, K. Suresh,A. J. Rosenberg,F. Worden,C. H. Chung,E. E. Vokes,C. Brenner, J. B. McHugh, Y. Zhai, T. Fu,R. Winkler,P. L. Swiecicki

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS（2024）

引用0浏览0引用

A Phase 2 Study of Alrizomadlin (APG-115) in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Cutaneous Melanoma That Has Failed Immuno-Oncologic (IO) Drugs

Montaser F. Shaheen,Jennifer Margaret Segar,Bartosz Chmielowski,Joseph J. Drabick,Meredith McKean,James A. Reeves,Christos Stelios Karapetis,Marlana M. Orloff,Anthony W. Tolcher, Thaddeus,Brian Gastman, Asit De, Ben Paudyal,Robert E. Winkler,Mingyu Li,Mohammad Ahmad,Dajun Yang,Yifan Zhai

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用0浏览0引用

A Phase 2 Study of Alrizomadlin, a Novel MDM2/p53 Inhibitor, in Combination with Pembrolizumab for Treatment of Patients with Malignant Peripheral Nerve Sheath Tumor (MPNST)

Neeta Somaiah,Brian Andrew Van Tine,Bartosz Chmielowski,Joseph J. Drabick,Sant P. Chawla,Meredith McKean,Alexander I. Spira,Kenneth John O'Byrne,Steven A. Foresto,Sujana Movva,AeRang Kim,Brian Gastman,Joseph Gerald Pressey, Ben Paudyal, Asit De,Robert E. Winkler,Mingyu Li,Mohammad Ahmad,Dajun Yang,Yifan Zhai

Journal of clinical oncologyno. 16_suppl (2023): e14627-e14627

引用0浏览0引用

SHARE: Stakeholder Based Analysis of Research for Decommissioning

Roger Garbil, Seif Ben Hadj Hassine, Patrick Blaise,Cécile Ferry,Robert Winkler,Laura Aldave de las Heras,Federica Pancotti,Anthony W. Banford, Kurt Van den Dungen,Réka Szőke, Gintautas Poškas, Angelika Bohnstedt,Muhammad Junaid Ejaz Chaudhry

EPJ - Nuclear Sciences & Technologies (2023)

引用0浏览0引用

Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER plus ) breast cancer or advanced solid tumors

Kevin Kalinsky,Anthony W. Tolcher,Shushen Wang,Funda Meric-Bernstam,Robert Winkler,Mingyu Li,Xuemei Sun,Wentao Pan,Bishnuhari Paudyal,Zhiyan Liang,Ming Lu,Dajun Yang,Yifan Zhai

Journal of Clinical Oncology（2022）

引用0浏览0引用

Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

Matthew S. Davids,Asher Chanan-Khan,Boyd Mudenda,Larysa Nogaieva,Iryna Kriachok, Hanna Usenko,Vladimir Ivanov,Olena Kyselova, Tetiana Perekhrestenko, Ivan Muzhychuk,Alexander Myasnikov,Zvenyslava Maslyak,Andrew Proidakov,Olga Uspenskaya,Elena Borisenkova,Paula Marlton,Tanya Siddiqi,Allison Winter, Tamila Lysa,Bulat Bakirov, Lei Fu, Zi Chen, Min Yu, Mingyu Li, Laura Glass,Mohammad Ahmad, Olena Karpenko,Iurii Osipov, Asit De, Ben Paudyal,Hengbang Wang,Robert Winkler,Nashat Gabrail, Vinod Ganju,Tatiana S. Konstantinova,Olga S. Samoylova,Dajun Yang,Yifan Zhai

Blood（2022）

引用1浏览0引用

Trial in Progress: A Phase I/II Trial of Novel MDM2 Inhibitor Alrizomadlin (APG-115), with or Without Platinum Chemotherapy, in Patients with P53 Wild-Type Salivary Gland Carcinoma

Paul Swiecicki,Yuefen Tang,Alexander T. Pearson,Jameel Muzaffar,Mary J. Fidler,Robert Winkler,Tommy Fu,Mingyu Li,Mohammad Ahmad,Dajun Yang,Yifan Zhai

Journal of clinical oncology（2021）

引用2浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn